Agomab Therapeutics CEO Tim Jasper Knotnerus buys $94,880 common shares

Tim Jasper Knotnerus bought 11,000 common shares in open-market purchases at USD 8.48—8.70, raising his directly held stake to 21,823 shares. A further 34,394 shares were reported as indirectly held via TJK Life Sciences B.V.